AVADEL PHARMACEUTICALS PLC's ticker is and the CUSIP is 05337M954. A total of 2 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $233,810 | -95.1% | 22,700 | -92.2% | 0.00% | -93.3% |
Q2 2023 | $4,769,312 | +1379.2% | 289,400 | +722.2% | 0.02% | +1400.0% |
Q1 2023 | $322,432 | -14.4% | 35,200 | -33.1% | 0.00% | 0.0% |
Q4 2022 | $376,616 | +131.1% | 52,600 | +61.8% | 0.00% | – |
Q3 2022 | $163,000 | +68.0% | 32,500 | -18.5% | 0.00% | – |
Q2 2022 | $97,000 | -55.9% | 39,900 | +23.9% | 0.00% | – |
Q1 2022 | $220,000 | +120.0% | 32,200 | +159.7% | 0.00% | – |
Q4 2021 | $100,000 | +614.3% | 12,400 | +785.7% | 0.00% | – |
Q3 2021 | $14,000 | -70.8% | 1,400 | -80.3% | 0.00% | – |
Q2 2021 | $48,000 | -85.3% | 7,100 | -80.3% | 0.00% | – |
Q1 2021 | $326,000 | +128.0% | 36,100 | +68.7% | 0.00% | – |
Q4 2020 | $143,000 | +50.5% | 21,400 | +13.8% | 0.00% | – |
Q3 2020 | $95,000 | -48.4% | 18,800 | -17.5% | 0.00% | -100.0% |
Q2 2020 | $184,000 | -46.0% | 22,800 | -47.0% | 0.00% | -66.7% |
Q1 2020 | $341,000 | +45.7% | 43,000 | +38.7% | 0.00% | +50.0% |
Q4 2019 | $234,000 | – | 31,000 | +30900.0% | 0.00% | – |
Q2 2019 | $0 | -100.0% | 100 | -98.9% | 0.00% | – |
Q4 2018 | $22,000 | -73.8% | 8,700 | -54.5% | 0.00% | -100.0% |
Q3 2018 | $84,000 | +104.9% | 19,100 | +185.1% | 0.00% | – |
Q2 2018 | $41,000 | -84.4% | 6,700 | -81.4% | 0.00% | -100.0% |
Q1 2018 | $263,000 | +511.6% | 36,100 | +581.1% | 0.00% | – |
Q4 2017 | $43,000 | +760.0% | 5,300 | +960.0% | 0.00% | – |
Q3 2017 | $5,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
GROUP ONE TRADING, L.P. | 39,900 | $97,000 | 0.00% |
JANE STREET GROUP, LLC | 22,600 | $55,000 | 0.00% |